The prospective multicenter observational cohort study will be offered consecutively to any patient with primary or secondary myelofibrosis or with Polycythemia Vera who has initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The main purpose is to assess adherence to ruxolitinib using the ARMS questionnaire. Each individual patient will be administered the questionnaire at the first convenient opportunity, regardless of when ruxolitinib is started, and again after 4, 8, 12, 24, and 48 weeks, in conjunction with drug procurement.
The prospective multicenter observational cohort study will be offered consecutively to any patient with primary or secondary myelofibrosis or with Polycythemia Vera who has initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. Laboratory tests and histologic, cytogenetic, molecular, and radiologic investigations performed by the patient and collected for study will be conducted in accordance with clinical practice, independent of the patient's participation in the study. In particular, data related to systemic symptoms and splenomegaly will be collected at diagnosis and disease reassessments performed in the context of normal clinical practice. These data will be collected at the first administration of the ARMS questionnaire and again after 12, 24, and 48 weeks. If performed, any additional assessments will also be recorded. Each individual patient will be administered the questionnaire (ARMS) at the first convenient opportunity, regardless of the time of initiation of ruxolitinib, and again after 4, 8, 12, 24, and 48 weeks, in conjunction with drug procurement. If in-person data collection is not possible, the mode of data collection by telephone interview will be adopted. The minimum expected duration of individual patient observation is 48 weeks.
Study Type
OBSERVATIONAL
Enrollment
189
Azienda Ospedaliera Annunziata
Cosenza, Calabria, Italy
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
Reggio Calabria, Calabria, Italy
Università degli Studi di Napoli Federico II - U.O.C. di Ematologia e Trapianti di midollo
Naples, Campania, Italy
IRCCS Policlinico Sant'Orsola
Bologna, Emilia-Romagna, Italy
Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna
Ferrara, Emilia-Romagna, Italy
Adherence
Incidence of low adherence to ruxolitinib therapy, and the features associated with low adherence
Time frame: 2 years
Distress
Emotional distress is measured based on a visual analogue scale with the distress thermometer, a simple and quick (3-4 minutes) tool that investigates the areas most involved in distress (minimum value: 0, lower distress; maximum value: 10, higher distress)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Azienda Ospedaliero-Universitaria di Parma
Parma, Emilia-Romagna, Italy
AUSL di Piacenza - Palazzine Medicine Specialistiche
Piacenza, Emilia-Romagna, Italy
Dipartimento Oncoematologico - AUSL della Romagna
Ravenna, Emilia-Romagna, Italy
Arcispedale Santa Maria Nuova - IRCCS
Reggio Emilia, Emilia-Romagna, Italy
Ospedale Infermi di Rimini
Rimini, Emilia-Romagna, Italy
...and 18 more locations